Boehringer Ingelheim Animal Health announced that the U.S. Food and Drug Administration Center for Veterinary Medicine (FDA-CVM) has granted conditional approval of VETMEDIN®-CA1 (pimobendan), which is indicated for the delay of onset of congestive heart failure in dogs with Stage B2 preclinical myxomatous mitral valve disease (MMVD), a form of chronic valvular heart disease in dogs. Based on a study, dogs treated with VETMEDIN-CA1 demonstrated an average of 15 months of a prolonged, symptom-free life compared to dogs treated with a placebo.
VETMEDIN-CA1 will be available by veterinary prescription in 1.25 mg and 5.0 mg chewable tablets beginning Q3 2022.
According to the American College of Veterinary Internal Medicine (ACVIM), MMVD is the most common heart disease of dogs in many parts of the world, accounting for approximately 75% of heart disease cases seen in dogs by veterinary practices in North America. It is estimated that approximately 10% of dogs presented to primary care veterinary practices have heart disease.